Targeted Therapies Forum Presented in English 2023 - Q&A Video Series 3

Article and Video CATEGORIES

Cancer Journey

ABOUT

Sandip Patel, MD, is a board-certified medical oncologist who specializes in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancer. Dr. Patel is focused on developing personalized therapies that stimulate a patient’s immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types.

Targeted Therapies Forum Presented in English 2023 - Q&A Video Series 3

AlexandraGBeneke

Mon, 10/09/2023 - 14:57

Our Targeted Therapies Forum online event includes a Q&A session where our amazing faculty answers questions from the audience. This is the third batch of videos for our morning Q&A session.

Author

Sandip P. Patel, MD, GRACE Faculty

Targeted Therapies Forum presented in English

This next series of videos from the Q&A sessions includes the following videos:

Q&A: What Are the Platform Options for SBRT?
Why Some Patients Remain on TKIs Without Acquiring Resistance?
High PD-L1:Wait for Genetic Testing Results Before Treatment?

To watch the complete playlist click here.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.